


# Journal Pre-proof

FR-La importancia de la invasión linfovascular en el carcinoma escamoso cutáneo

M. Luque-Luna J. Gil-Lianes A. Toll-Abelló



PII: S0001-7310(25)00211-X

DOI: <https://doi.org/doi:10.1016/j.ad.2025.03.024>

Reference: AD 4325

To appear in: *Actas dermosifiliograficas*

Received Date: 2 October 2023

Accepted Date: 1 September 2024

Please cite this article as: Luque-Luna M, Gil-Lianes J, Toll-Abelló A, FR-La importancia de la invasión linfovascular en el carcinoma escamoso cutáneo, *Actas dermosifiliograficas* (2025), doi: <https://doi.org/10.1016/j.ad.2025.03.024>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2025 Published by Elsevier España, S.L.U. on behalf of AEDV.

Refers to AD\_4258

Foro de Residentes

## FR-La importancia de la invasión linfovascular en el carcinoma escamoso cutáneo

[[Translated article]]RF-The Significance of Lymphovascular Invasion in Cutaneous Squamous Cell Carcinoma

**Autores:** M. Luque-Luna , J. Gil-Lianes, A. Toll-Abelló

Servicio de Dermatología del Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, España.

**Autor para correspondencia:**

Mar Luque Luna

Email: mar.luqueluna@gmail.com

**Palabras clave:** Carcinoma escamoso cutáneo; BWH; AJCC; Invasión linfovascular

**Keywords:** Cutaneous squamous cell carcinoma; BWH; AJCC; Lymphovascular invasion

Cutaneous squamous cell carcinoma (cSCC) represents between 20% and 50% of malignant cutaneous tumors. Most are cured with surgery, presenting a subgroup of them with poor prognosis despite surgical treatment, due to local recurrence (LR), in-transit metastases (ITM), nodal metastases (NM), distant metastases (DM), or disease-specific death (DSD). Staging systems stratify tumor prognosis and optimize its treatment (table 1).

Although lymphovascular invasion (LVI) is associated with DSD and DM in cSCC, it is excluded from staging systems because there is insufficient data for its independent prognostic significance<sup>1</sup>. Some authors describe an increased risk of metastasis in cSCC with LVI<sup>2-4</sup>. Other authors have not shown a statistically significant association<sup>5</sup>.

Moore et al. (n=193) conducted a prospective study concluding that cSCC cases of the head and neck with LVI+ were statistically significantly associated with NM ( $p < 0.0001$ )<sup>2</sup>.

Gupta et al.<sup>4</sup> conducted a retrospective multicenter cohort study to define risk factors in low-risk cSCC (specifically in the BWH T2a stage) that are associated with NM, DM, and DSD. They concluded that 1 major criterion (tumor diameter  $\geq 40$  mm, poor differentiation, invasion beyond subcutaneous tissue, large-caliber perineural invasion) and  $\geq 1$  minor criteria (subcutaneous fat tissue invasion, moderate differentiation, small-caliber perineural invasion, or lymphovascular invasion) were predictive of worse prognosis, with a cumulative incidence of poor prognosis events of 8% (95%CI, 5.1-13.7) in T2a cSCC vs 2.8% (95%CI, 1.9-4.1) in other T2a tumors.

Kus et al.<sup>3</sup> (n = 10,707) conducted the first multicenter study to evaluate the impact of LVI on cSCC prognosis. They included retrospective cohorts of cSCC patients from Brigham and Women's Hospital (BWH) and Cleveland Clinic Foundation, with cSCC diagnosed between March 1999 and October 2020. The statistical analysis was performed by separating low- (T1, T2a) and high-risk (T2b, T3) tumors according to BWH. They analyzed a total of 10,707 cSCC: 78 presented LVI+. In low-risk stages, the authors found a higher cumulative incidence of LR (LVI+: 12.3%; LVI-: 1.1%;  $p < 0.01$ ), metastases, whether in-transit, nodal, or distant (LVI+: 4.2%; LVI-: 0.4%;  $p < 0.01$ ), and DSD (LVI+: 16.2%; LVI-: 0.4%;  $p < 0.01$ ). In high-risk stages, LVI+ tumors presented higher rates of metastases at 5 years (LVI+: 28.5%; LVI-: 16.8%;  $p = 0.06$ ) and DSD (LVI+: 25.3%; LVI-: 13.9%;  $p = 0.03$ ), without any differences being reported in LR (LVI+: 16.3%; LVI-: 15.8%;  $p = 0.11$ )<sup>3</sup>.

In low-risk cSCC, LVI+ becomes more important, presenting 12, 10, and 41 times more risk of LR, metastases, and DSD, respectively, vs LVI- cSCC. By presenting at most one of the risk factors established in the staging systems, in LVI+ with poor prognosis events, LVI should acquire more importance in staging in the absence of other factors.

We consider that staging systems should include LVI as a predictor of poor prognosis in cSCC.

## References

< BIBL >

< BIB >

1

S Ruiz F E.S.

S Karia F P.S.

S Besaw F R.

S Schmults F C.D.

AT Performance of the American Joint Committee on Cancer Staging Manual, 8<sup>th</sup> Edition vs the Brigham and Women's Hospital Tumor Classification System for Cutaneous Squamous Cell Carcinoma

JT JAMA Dermatol

V 155

D 2019

P 819-L 825

< original\_ref> Ruiz E.S., Karia P.S., Besaw R., Schmults C.D., Performance of the American Joint Committee on Cancer Staging Manual, 8<sup>th</sup> Edition vs the Brigham and Women's Hospital Tumor Classification System for Cutaneous Squamous Cell Carcinoma, JAMA Dermatol, 155, 2019, 819- 825< /original\_ref>

< /BIB>

< BIB>

2

S Moore F B.A.

S Weber F R.S.

S Prieto F V.

S El-Naggar F A.

S Holsinger F F.C.

S Zhou F X.< ET-AL>

AT Lymph node metastases from cutaneous squamous cell carcinoma of the head and neck

JT Laryngoscope

V 115

D 2005

P 1561-L 1567

< original\_ref> Moore B.A., Weber R.S., Prieto V., El-Naggar A., Holsinger F.C., Zhou X., Lymph node metastases from cutaneous squamous cell carcinoma of the head and neck, Laryngoscope, 115, 2005, 1561- 1567< /original\_ref>

< /BIB>

< BIB>

3

S Kus F K.J.B.

S Murad F F.

S Smile F T.D.

S Chang F M.

S Ashrafzadeh F S.

S Zhou F G.< ET-AL>

AT Higher metastasis and death rates in cutaneous squamous cell carcinomas with lymphovascular invasion

JT J Am Acad Dermatol

V 86

D 2022

P 766-L 773

< original\_ref> Kus K.J.B., Murad F., Smile T.D., Chang M., Ashrafzadeh S., Zhou G., Higher metastasis and death rates in cutaneous squamous cell carcinomas with lymphovascular invasion, J Am Acad Dermatol, 86, 2022, 766- 773< /original\_ref>

< /BIB>

< BIB>

4

S Gupta F N.

S Weitzman F R.E.

S Murad F F.

S Koyfman F S.A.

S Smile F T.D.

S Chang F M.S.< ET-AL>

AT Identifying Brigham and Women's Hospital stage T2a cutaneous squamous cell carcinomas at risk of poor outcomes

JT J Am Acad Dermatol

V 86

D 2022

P 1301-L 1308

< original\_ref> Gupta N., Weitzman R.E., Murad F., Koyfman S.A., Smile T.D., Chang M.S., Identifying Brigham and Women's Hospital stage T2a cutaneous squamous cell carcinomas at risk of poor outcomes, J Am Acad Dermatol, 86, 2022, 1301- 1308< /original\_ref>

< /BIB>

< BIB>

5

S Brougham F N.D.L.S.

S Dennett F E.R.

S Cameron F R.

S Tan F S.T.

AT The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factors

JT J Surg Oncol

V 106

D 2012

P 811-L 815

< original\_ref> Brougham N.D.L.S., Dennett E.R., Cameron R., Tan S.T., The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factors, J Surg Oncol, 106, 2012, 811- 815< /original\_ref>

< /BIB>

< /BIBL>

**Table 1.** CEC classification according to BWH and AJCC*BWH*

T1 0 high-risk factors

T2a 1 high-risk factor

T2b 2-3 high-risk factors

T3 4 high-risk factors or bone invasion

*AJCC 8<sup>th</sup> edition*

T1 &lt; 2 cm in greatest diameter

T2  $\geq$  2 cm but < 4 cm in greatest diameter

T3  $\geq$  4 cm in greatest diameter or minor bone invasion or perineural invasion (tumor cells in the nerve sheath deeper than the dermis or  $\geq$  0.1 mm in caliber or with clinical or radiographic nerve involvement without skull base invasion or transgression) or deep invasion (beyond subcutaneous fat or > 6 mm measured from the granular layer of preserved epidermis to the base of the tumor)

T4a Tumor with macroscopic invasion of cortical bone and/or bone marrow

T4b Tumor with invasion of skull bone and/or skull base foramen

High-risk factors in BWH classification are tumor diameter  $\geq$  2 cm. Poor histological differentiation. Perineural invasion of nerves  $\geq$  0.1 mm in caliber. Tumor invasion beyond subcutaneous fat (excluding bone invasion, which directly classifies as T3).

AJCC: American Joint Committee on Cancer; BWH: Brigham and Women's Hospital; CEC: Cutaneous Squamous Cell Carcinoma

Source: Adapted from Ruiz et al.<sup>1</sup>